Filtered By:
Procedure: Lower Endoscopy
This page shows you your search results in order of relevance. This is page number 15.
Order by Relevance | Date
Total 241 results found since Jan 2013.
Association of spontaneous cerebrospinal fluid rhinorrhea with transverse venous sinus stenosis: a retrospective matched case ‐control study
ConclusionIn this retrospective study, sCSF leaks were strongly associated with VSS. This novel finding provides a rationale for further investigation of the role of VSS in the onset of sCSF leaks and of the potential interest in venous stenting after the surgical repair of leaks.
Source: International Forum of Allergy and Rhinology - December 6, 2020 Category: Allergy & Immunology Authors: Vincent Bedarida,
Marc ‐Antoine Labeyrie,
Michael Eliezer,
Jean‐Pierre Saint‐Maurice,
Clément Jourdaine,
Sergios Gargalas,
Philippe Herman,
Emmanuel Houdart,
Benjamin Verillaud Tags: ORIGINAL ARTICLE Source Type: research
Janssen Presents Results of First Head-to-Head Study of Biologic Therapies in Patients with Moderate to Severe Crohn ’s Disease
SPRING HOUSE, PENNSYLVANIA, May 23, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced efficacy and safety data for STELARA® (ustekinumab) in Crohn’s disease (CD) and ulcerative colitis (UC),1-4including data from the SEAVUE study, the first head-to-head study of biologic therapies in patients with CD, presented in a Clinical Science Late-Breaking Abstract Plenary session.1 SEAVUE data showed treatment with STELARA demonstrated high rates of clinical remission, corticosteroid-free remission, clinical response and endoscopic response through one year in biologic-naïve patients with mo...
Source: Johnson and Johnson - May 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Central compartment atopic disease: outcomes compared with other subtypes of chronic rhinosinusitis with nasal polyps
ConclusionRates of polyp recurrence and revision ESS were significantly lower in CCAD patients compared with patients with other CRSwNP subtypes, suggesting durable benefit of ESS and postoperative medical therapy in CCAD patients.
Source: International Forum of Allergy and Rhinology - June 2, 2021 Category: Allergy & Immunology Authors: Andrew J. Steehler,
Jackson R. Vuncannon,
Sarah K. Wise,
John M. DelGaudio Tags: ORIGINAL ARTICLE Source Type: research
Effects of implants with steroids after endoscopic sinus surgery: A systematic review with meta ‐analysis of randomized controlled trials
ConclusionsCollectively, steroid implant decreases LKE and POSE among patients receiving ESS in the short term, but long-term effects remain unclear. Patient-based outcomes are worth further discussion in the future.
Source: International Forum of Allergy and Rhinology - June 16, 2021 Category: Allergy & Immunology Authors: Yi ‐Lin Kao,
Yi‐Chen Huang,
Shao‐Chen Tsai,
Ming‐Tang Lai,
Yi‐No Kang Tags: ORIGINAL ARTICLE Source Type: research
Relationship between socioeconomic status, exposure to airborne pollutants, and chronic rhinosinusitis disease severity
ConclusionLower SES predicted higher exposure to air pollution and increased disease severity in patients with CRS as demonstrated by the increased need for steroid treatment.
Source: International Forum of Allergy and Rhinology - September 12, 2021 Category: Allergy & Immunology Authors: Nathalia Velasquez,
Lauren Gardiner,
Tracy Z. Cheng,
John A. Moore,
Robert M. Boudreau,
Albert A. Presto,
Stella E. Lee Tags: ORIGINAL ARTICLE Source Type: research
New Analysis Presented by Janssen at United European Gastroenterology Week (UEGW) Demonstrates Long-Term Safety Profile for STELARA ® (ustekinumab) in Older Patients Across Approved Indications
SPRING HOUSE, PENNSYLVANIA, October 4, 2021 – Today, the Janssen Pharmaceutical Companies of Johnson & Johnson announced a new analysis of STELARA® (ustekinumab) pooled safety data from 13 clinical studies across approved indications, showing rates of key safety events among adults 60 years and older treated with STELARA for up to five yearsa were similar to rates observed with placebo during the control phase of these trials.1,b Approved indications included adults with moderately to severely active Crohn’s disease (CD), moderately to severely active ulcerative colitis (UC), moderate to severe plaque psoriasis (P...
Source: Johnson and Johnson - October 4, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Olfaction in COPD
CONCLUSIONS: COPD is associated with olfactory dysfunction and the underlying mechanisms for this dysfunction should be elucidated.PMID:34647543 | DOI:10.4193/Rhin21.037
Source: Rhinology - October 14, 2021 Category: ENT & OMF Authors: W M Thorstensen M R Øie S B Dahlslett M Sue-Chu S K Steinsv åg A S Helvik Source Type: research
Innovative application of internal carotid artery embolization in salvage endoscopic nasopharyngectomy for recurrent nasopharyngeal carcinoma: A case ‐matched comparison
ConclusionsThe innovative application of ICA embolization in endoscopic surgery in patients with rNPC invading the ICA significantly improved patient survival and reduced the risk of treatment-related complications. Therefore, this may be a safe and effective method with potential to improve the outcomes in rNPC patients.This article is protected by copyright. All rights reserved
Source: International Forum of Allergy and Rhinology - November 13, 2021 Category: Allergy & Immunology Authors: Wanpeng Li,
Qiang Liu,
Huan Wang,
Huangkang Zhang,
Quan Liu,
Li Hu,
Houyong Li,
Jiong Dai,
Xicai Sun,
Hongmeng Yu,
Dehui Wang Tags: ORIGINAL ARTICLE Source Type: research
Janssen Reports Positive Topline Week 48 Phase 2 Results for TREMFYA ® (guselkumab) in Adults With Moderately to Severely Active Crohn's Disease
SPRING HOUSE, PENNSYLVANIA, November 17, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced topline results from the Phase 2 GALAXI 1 clinical trial which showed rates of clinical remission (Crohn’s Disease Activity Index [CDAI]<150) previously reported at week 12 increased at week 48 among adults with moderately to severely active Crohn’s disease (CD) treated with TREMFYA® (guselkumab).1 At week 48, 65 percent of patients receiving TREMFYA achieved clinical remission. TREMFYA is under investigation and not currently approved for the treatment of CD in the U.S.2Janssen previously...
Source: Johnson and Johnson - November 17, 2021 Category: Pharmaceuticals Source Type: news
Endoscopic endonasal repair of anterior cranial base encephaloceles: A lower cost alternative to open craniofacial approaches
Source: International Forum of Allergy and Rhinology - January 1, 2022 Category: Allergy & Immunology Authors: Matthew J. Wu,
Fuad M. Baroody,
Christopher R. Roxbury Tags: RESEARCH NOTE Source Type: research
What Are Common Gastrointestinal Polyposes in Children?
Discussion
Bloody stools or blood in the diaper is a relatively common complaint in general pediatrics. For most patients it is often a minor concern. Commonly it is a transient problem (e.g. rectal fissure caused by constipation or trauma) or often not blood (e.g. urate crystals in the diaper, food, menses, etc.). Real blood does occur with an identifiable cause such as long distance running or heavy exercise, or milk protein allergy/sensitivity that improves with a milk-restricted diet. Many more serious causes are associated with heavier or more recalcitrant bleeding, increased defecation, abdominal pain, poor eating an...
Source: PediatricEducation.org - January 24, 2022 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news
